The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
D. Ross Camidge
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Sai-Hong Ignatius Ou
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Geoffrey Shapiro
Research Funding - Pfizer
Gregory Alan Otterson
Research Funding - Pfizer
Liza Cosca Villaruz
No relevant relationships to disclose
Miguel Angel Villalona-Calero
No relevant relationships to disclose
A. John Iafrate
Consultant or Advisory Role - Pfizer
Marileila Varella-Garcia
Research Funding - Merck Serono
Sanja Dacic
No relevant relationships to disclose
Stephanie Cardarella
No relevant relationships to disclose
Weiqiang Zhao
No relevant relationships to disclose
Lesley Tye
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Patricia Stephenson
Consultant or Advisory Role - Pfizer
Keith D. Wilner
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Leonard Philip James
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Other Remuneration - Pfizer
Mark A. Socinski
Research Funding - Pfizer